This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
5 ETFs That Deserve a Place in Your Portfolio
by Sweta Jaiswal, FRM
Here we discuss some ETFs that can be good additions to investors' portfolio in 2021.
Play These ETF Strategies to Ride the US Market Optimism
by Sweta Jaiswal, FRM
Let's look at some ETF strategies to help investors gain from optimism surrounding the chances of another trench of coronavirus-aid package and improved coronavirus vaccine rollout.
5 ETFs to Enhance Your Portfolio in 2021
by Sweta Jaiswal, FRM
Here we discuss some ETFs that can be good additions to investors' portfolio for enhancing returns in 2021.
5 ETFs to Buy for the Blue Wave
by Sanghamitra Saha
Democrats taking control of both House and Senate and the OPEC output cut deal coming in favorable for markets, these ETFs should stay strong in January.
A Sneak Peek Into Popular ETF Investing Areas for Q1
by Sweta Jaiswal, FRM
Let's check out some ETF areas that can be solid investment picks in the first quarter of 2021 even as the coronavirus cases continue to rise.
5 ETFs to Add to Your Portfolio in 2021
by Sweta Jaiswal, FRM
Here we discuss some ETFs that can be good additions to investors' portfolio for enhancing returns in 2021.
Here's the Right ETF Mix for an Impressive New Year Portfolio
by Sweta Jaiswal, FRM
Here we highlight some ETF areas that investors can consider to make a strong and impressive portfolio this New Year.
5 Small-Cap ETFs Set to Explode on COVID-19 Vaccines
by Sweta Killa
As the economy seems on track for strong growth, a small-cap rally is expected to strengthen in the New Year.
Grab These ETFs Now for an Impressive Finish to 2020
by Sweta Jaiswal, FRM
Here we highlight some ETFs that can help investors make the most of the favorable investing opportunities amid the coronavirus crisis.
ETF Strategies to Gain From Vaccine Hopes & Biden's Transition
by Sweta Jaiswal, FRM
Let's look at some ETF strategies to help investors gain from the upbeat coronavirus vaccine data amid the health crisis.